In recent years, nickel-titanium shape memory alloys, as a core and critical material for high-end medical devices, have seen their applications continue to expand in the fields of neurointerventional and cardiovascular interventional procedures. The COMETIU self-expanding intracranial drug-eluting stent system, developed by Sino Medical's subsidiary Sino Shenchang, has successfully obtained EU MDR CE certification, becoming the first intracranial stent in its category worldwide to receive this certification. This breakthrough would not have been possible without the robust support provided by nickel-titanium alloy materials.
Intracranial vascular surgery imposes nearly exacting requirements on implanted devices: given the tortuous and delicate nature of the blood vessels, stents must combine superelasticity, fatigue resistance, and radial support while also offering excellent biocompatibility-making nickel-titanium alloy the ideal material for this application. The newly approved COMETIU stent features a matrix precision-machined from a nickel-titanium alloy tube. Leveraging the unique shape memory and superelastic properties of nickel-titanium alloy, the stent can be delivered in a compressed state through narrow, tortuous intracranial vessels via a delivery system. Upon reaching the lesion site, it automatically expands to conform to the vessel wall, providing stable support for the stenotic vessel.
In addition to the nickel-titanium alloy substrate, the product features a dual-layer coating design: a base layer of PBuMA and an upper layer of biodegradable PLGA coated with sirolimus. Combining a proprietary closed-loop asymmetric mesh structure with controlled-release drug delivery technology, the stent ensures a good fit with the blood vessel while releasing the drug to inhibit restenosis, directly addressing the clinical challenges of intracranial atherosclerotic stenosis. This product is intended for patients with vascular stenosis exceeding 70% who have not responded well to drug therapy. It is suitable for reference vessel diameters of 2.0–4.5 mm and can treat lesions up to 34 mm in length. The product undergoes electron beam sterilization and has a shelf life of two years.
The EU Medical Device Regulation (MDR) represents the highest global entry threshold for high-risk implantable medical devices. Compared to the previous Medical Devices Directive (MDD), the MDR has raised standards across the board-including clinical evidence, technical documentation, production quality control, and post-market surveillance-significantly increasing the difficulty of the review process. Successfully passing the rigorous MDR review not only demonstrates that Sino Medical's product design and manufacturing quality control systems meet international standards but also indirectly confirms that China's nickel-titanium alloy processing, precision engraving, and coating technologies have joined the global top tier.
For a long time, the domestic high-end neurointerventional market was dominated by overseas products, and domestically produced devices faced significant challenges in breaking into mainstream markets in Europe and the United States. Intracranial stents are classified as Class III high-risk implantable devices, and the entire production chain-from tube preparation, laser cutting, deburring, and surface modification to drug-eluting coating-is characterized by extremely high technical barriers. The purity, uniformity, and fatigue resistance of nickel-titanium alloy tubing directly determine the safety of stents during long-term use within human blood vessels, so no detail in the manufacturing process can be overlooked. Of course, obtaining EU MDR certification is only the first step for domestic medical devices to enter international markets. This certification applies only to the European Union and the European Economic Area; registration applications must still be submitted separately for other countries and regions. Successful overseas commercialization also requires completing a series of tasks, including registration in various countries, channel development, hospital access, and health insurance negotiations. Coupled with uncertainties such as policy changes, the accumulation of clinical data, and exchange rate fluctuations, it will be difficult to achieve large-scale results in the short term. Technical certification does not equate to commercial success; the overseas market for neurointerventional devices has a long incubation period, and it will take time to realize profits.
Looking at the industry as a whole, specialty functional metal materials-such as nickel-titanium alloys-are becoming the key driver for domestic high-end medical devices to break into international markets. From coronary stents to intracranial interventional devices, domestic companies are gradually moving away from simply exporting low-end consumables and are advancing toward exporting high-end implantable devices based on original innovation. Materials form the foundation of medical devices. Only through continuous improvements in the performance of nickel-titanium alloys and precision machining processes can more innovative domestic medical devices consistently secure entry into international markets. While domestic neurointerventional devices have achieved major breakthroughs in certification, there remains a long road ahead across multiple fronts-including materials, manufacturing processes, clinical applications, and commercialization-to truly capture overseas markets on a large scale. As China's specialty alloy materials industry continues to mature, more innovative domestic medical devices built on advanced metallic materials are likely to take the global stage in the future.
E-mail: garychen3215@hotmail.com
Address: No.35, Baoti Rd, Baoji city, Shaanxi Province, China
Contact: Mr. Gary Chen
Phone: +86-917-8883215
Mobile/WhatsApp: +86 13092900605
